Azitra, Inc. will present updates on ATR-COSF and ATR-04 on September 14, 2026, including a rash program affecting approximately 150,000 people in the United States. Investors will hear initial ATR-COSF data, continued clinical enrollment information and the company’s progress across cosmetic and therapeutic applications.

Key Highlights

  • The ATR-COSF update will include initial data supporting cosmetic applications targeting fine lines and wrinkles.
  • Registered investors and potential partners will have access to one-on-one meetings during the conference.
  • Azitra will present updates on its ATR-COSF and ATR-04 programs beginning September 14, 2026.
  • Initial ATR-COSF data support expansion into cosmetic applications for fine lines and wrinkles.

Azitra, Inc. (AMEX: AZTR) will present updates on its ATR-COSF and ATR-04 programs at an investor conference beginning September 14, 2026.

The update will cover recent progress and pipeline activity, including initial ATR-COSF data supporting the company’s expansion into cosmetic applications for fine lines and wrinkles. The presentation will be available through an online conference link.

One-on-One Meetings With Investors and Potential Partners

Azitra said Whitfill will hold individual meetings with registered investors and potential partners during the conference. The presentation will also cover Azitra’s microbial Genetic Engineering platform, including its application beyond traditional therapeutics and its work on cosmetic proteins and peptides.